Source-grounded facts extracted from Solana Co's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Solana Co reported financial results for the fiscal quarter and year ended December 31, 2025.
“On March 30, 2026, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
Solana Co engaged CBIZ CPAs P.C. as its auditor.
“On October 15, 2025, the Committee approved the appointment of CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Baker Tilly US, LLP resigned as auditor of Solana Co.
“On October 15, 2025, the Audit Committee (the “Committee”) of the Board of Directors of Solana Corporation (formerly known as Helius Medical Technologies, Inc.) (the “Company”) received the resignation of Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm, effective immediately.”
Solana Co: Second Amended and Restated Bylaws amended solely to reflect the name change to Solana Company (effective 2025-09-29).
“Additionally, the Board approved an amendment to the Company’s Second Amended and Restated Bylaws solely to reflect the Name Change (the “Third Amended and Restated Bylaws”). The Third Amended and Restated Bylaws will become effective immediately after the Name Change on September 29, 2025.”
Solana Co: Company name changed from Helius Medical Technologies, Inc. to Solana Company via Certificate of Amendment (effective 2025-09-29).
“On September 25, 2025, the Board of Directors (the “Board”) of Helius Medical Technologies, Inc. (the “Company”) approved an amendment to the Company’s Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on July 18, 2018 (the “Certificate of Incorporation”), to change the Company’s name to Solana Company (the “Name Change”). On September 26, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Certificate of Incorporation, which will effect the Name Change at 8:00 a.m. Eastern Time on September 29, 2025.”
Solana Co: Increased authorized common stock to 800,000,000 shares via Certificate of Amendment (effective 2025-09-15).
“On September 15, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Share Increase, which became effective as of September 15, 2025.”
Solana Co received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 7, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common s”
Solana Co reported quarter ended March 31, 2024 results: revenue $135 thousand, net income net loss of $2.5 million, EPS $3.08 per share.
“Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”). ● Q1 2024 revenue of $135 thousand, compared to $111 thousand in Q1 2023, reflecting increased product sales in both the U.S. and Canada . ● Closed on $6.4 million public offering, raising net proceeds of”
Solana Co entered into Placement Agency Agreement with Craig-Hallum Capital Group LLC valued at approximately $6.4 million (effective 2024-05-06).
“On May 6, 2024, Helius Medical Technologies, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Craig-Hallum Capital Group LLC (the “Placement Agent”) for the purchase and sale, in a registered public offering by the Company (the “Public Offering”) of 704,999 shares of its Class A common stock, par value $0.001 per share (“Common Stock”) and 2,147,222 pre-funded warrants, each to purchase one share of Common Stock at an exercise price of $0.001 per share (the “Pre-funded Warrants”) together with accompanying Series A Warrants to purchase up to 2,852,221 shares of its Common Stock (“Series A Warrants”) and Series B Warrants to purchase up to 2,852,221 shares of its Common Stock (“Series B Warrants”, and together with the Series A Warrants, the “Public Warrants”).”
Solana Co received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 4, 2024, Helius Medical Technologies, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Stock Market LLC because the Company’s stockholders' equity, as reported in the Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2023, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards.”
Solana Co reported financial results for the quarter and full year ended December 31, 2023.
“On March 28, 2024, Helius Medical Technologies, Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights.”
Solana Co: Amended and restated bylaws to reduce stockholder meeting quorum, address universal proxy rules, update disclosure requirements, impose new special meeting nomination conditions, and clarify personal jurisdiction (effective 2024-03-12).
“On March 12, 2024, the Board of Directors (the “ Board ”) of Helius Medical Technologies, Inc., a Delaware corporation (the “ Company ”) approved and adopted the Company’s Second Amended and Restated Bylaws (the “ Second Amended and Restated Bylaws ”), which became effective the same day.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.